STOCK TITAN

BiomX Inc. - $PHGE STOCK NEWS

Welcome to our dedicated page for BiomX news (Ticker: $PHGE), a resource for investors and traders seeking the latest updates and insights on BiomX stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BiomX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BiomX's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.82%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.61%
Tags
conferences earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.35%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.13%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.15%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.65%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
conferences earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.44%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
conferences clinical trial
BiomX Inc.

NYSE:PHGE

PHGE Rankings

PHGE Stock Data

19.11M
32.39M
29.82%
25.72%
0.4%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
NESS ZIONA

About PHGE

biomx is a microbiome drug discovery company developing customized phage therapies that target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease (ibd) and cancer. we discover and validate proprietary bacterial targets and customize our natural and engineered phage compositions against these targets. the company’s platforms use computational and synthetic biology and cutting-edge research from profs. rotem sorek, ph.d., eran elinav, m.d., ph.d., and eran segal, ph.d., of the weizmann institute of science; and professor timothy k. lu, m.d., ph.d., of the massachusetts institute of technology. investors in the company include orbimed israel incubator lp, johnson & johnson development corporation inc., takeda ventures, inc., seventure partners, mirae asset global investments, and sbi.